CXCR2 inhibition enables NASH-HCC immunotherapy.
Jack LeslieJohn B G MackeyThomas JamiesonErik Ramon-GilThomas M DrakeFrédéric FercoqWilliam ClarkKathryn GilroyAnn HedleyColin NixonSaimir LuliMaja LaszczewskaRoser PinyolRoger Esteban-FabróCatherine E WilloughbyPhilipp K HaberCarmen Andreu-OllerMohammad RahbariChaofan FanDominik PfisterShreya RamanNiall WilsonMiryam MüllerAmy CollinsDaniel GehAndrew FullerDavid McDonaldGillian HulmeAndrew FilbyXabier Cortes-LavaudNoha-Ehssan MohamedCatriona A FordXimena L Raffo IraolagoitiaAmanda J McFarlaneMisti V McCainRachel A RidgwayEdward W RobertsSimon T BarryGerard J GrahamMathias HeikenwälderHelen L ReevesJosep M LlovetLeo M CarlinThomas G BirdOwen J SansomDerek A MannPublished in: Gut (2022)
CXCR2-inhibition induces reprogramming of the tumour immune microenvironment that promotes ICI in NASH-HCC.
Keyphrases